Oxaliplatin induced pulmonary toxicity—a rare phenomenon

Oxaliplatin is a third generation platinum compound, which is usually used in combination with capecitabine or 5 fluorouracil for gastro-intestinal cancers. With Oxaliplatin based chemotherapy, the common adverse effects include neurological, hematological and gastrointestinal toxicities. Less common side effects includes dermatological, hepatic and pulmonary toxicities. Interstitial lung disease and pulmonary fibrosis were reported with Oxaliplatin based combination chemotherapy, but was not noticed when single agent Oxaliplatin was used. Here we report, a case of single agent Oxaliplatin induced interstitial lung disease.